来曲唑对晚期及绝经妇女乳腺癌治疗效果的Meta分析

目的评价联用来曲唑治疗晚期及绝经妇女乳腺癌的效果。方法检索近10年PubMed、Cochrane Data—base of Systematic Reviews、EMbase、中国知网、万方数据库关于来曲唑治疗乳腺癌的随机对照研究（RCT），同时筛检纳入文献的参考文献，对纳入研究的方法学进行评价。研究者对文献质量进行严格评价和资料提取，对符合质量标准的文献用Review Manager5．0软件进行Meta分析。结果共5篇文献9398例患者纳入研究，其中治疗组（使用来曲唑）4699例，对照组（使用他莫西芬）4699例，基线资料可比。Meta分析结果示治疗组远处转移、控制肿瘤面积、不良反应与对照组比较差异均有统计学意义（RR=0．82，95％CI（0．69，0．97）；RR=1．61，95％CI（1．46，1．77）；RR=0．87，95％CI（0．78，0．98）]。结论与传统的治疗方案比较，来曲唑可显著提高乳腺癌患者的治疗效果，且不良反应少。

Meta Analysis of Letrozole Treatment in Advanced Breast Cancer and Postmenopausal Breast Cancer

Objective To evaluate the efficacy of Letrozole treatment in advanced breast cancer and postmenopausal breast cancer.Methods We searched PubMed,Cochrane Database of Systematic Reviews,EMbase,CNKI,WANFANG Database about Letrozole treatment of breast cancer of randomized study(RCT),and screened our literature references published during the past 10 years,and evaluated them using Meta analysis with Review Manager 5.0 system.Results 5 literatures with a total of 9398 cases were included in the study;Treatment group(Letrozole,4699 cases) and control group(Tamoxifen,4699 cases).Meta-analysis results showed that there were significant differences in distant metastases,control of tumor size,adverse reactions between the two groups (RR=0.82,95%CI(0.69,0.97);RR=1.61,95%CI(1.46,1.77);RR=0.87,95%CI(0.78,0.98)].Conclusion Compared to conventional treatment,Letrozole can significantly improve the efficacy of treatment in breast cancer patients.